Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Annovis Bio, Inc./ 10-Q

Quarterly Report · 10-Q

Annovis Bio, Inc.

ANVSNYSEEQUITYCurrent

Quarterly Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 4:31 PM EDTCIK 1477845Accession 0001104659-26-097228
View company →Permanent SEC source ↗
Share

Company context

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Current securities

ANVSNYSE · EQUITY · Current

Recent company filings

  1. Entry into a Material Definitive Agreement · Regulation FD DisclosureNov 5, 2026
  2. 424B5 filingNov 5, 2026
  3. 424B5 filingNov 4, 2026
  4. Results of Operations and Financial Condition · Regulation FD Disclosure · Other EventsNov 4, 2026
  5. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security HoldersNov 4, 2026

Registered securities in this filing

Annovis Bio, Inc. · 10-Q · Filed 2026-08-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
ANVS
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: Duration_1_1_2026_To_6_30_2026_pcOlkEOu0EmZ79I9CKqwYQ

Dimensions: Not supplied

Accession 000110465926097228 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.